Nuvalent (NUVL) Accounts Payables (2020 - 2026)
Nuvalent's (NUVL) quarterly Accounts Payables came in at $22.1 million in Q1 2026, down 15.4% YoY from $26.2 million in Q1 2025, and down 26.6% on a QoQ basis from $30.2 million in Q4 2025.
Nuvalent (NUVL) Accounts Payables (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Accounts Payables data on file, last reported at $22.1 million in Q1 2026.
- Quarterly Accounts Payables fell 15.4% year-over-year to $22.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.1 million (down 15.4% YoY) and the FY2025 annual result came in at $30.2 million, up 477.19% from the prior year.
- Accounts Payables slipped to $22.1 million in Q1 2026, from $30.2 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $30.2 million in Q4 2025 to a low of $4.0 million in Q2 2022.
- A 5-year average of $12.3 million and a median of $9.3 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2024 — Accounts Payables plunged 43.66% — and 2025, when it surged 477.19%.
- Tracing NUVL's Accounts Payables over 5 years: stood at $7.2 million in 2022, then gained by 28.9% to $9.3 million in 2023, then plunged by 43.66% to $5.2 million in 2024, then surged by 477.19% to $30.2 million in 2025, then fell by 26.6% to $22.1 million in 2026.
- The last three Accounts Payables figures came in at $22.1 million (Q1 2026), $30.2 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 22.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.14 Mn |
| Dec 31, 2025 | 30.16 Mn |
| Sep 30, 2025 | 22.01 Mn |
| Jun 30, 2025 | 13.34 Mn |
| Mar 31, 2025 | 26.17 Mn |
| Dec 31, 2024 | 5.23 Mn |
| Sep 30, 2024 | 15.93 Mn |
| Jun 30, 2024 | 7.40 Mn |
| Mar 31, 2024 | 13.40 Mn |
| Dec 31, 2023 | 9.27 Mn |
| Sep 30, 2023 | 9.78 Mn |
| Jun 30, 2023 | 8.12 Mn |
| Mar 31, 2023 | 6.43 Mn |
| Dec 31, 2022 | 7.20 Mn |
| Sep 30, 2022 | 4.62 Mn |
| Jun 30, 2022 | 4.03 Mn |
| Mar 31, 2022 | 4.25 Mn |
| Dec 31, 2021 | 2.89 Mn |
| Sep 30, 2021 | 2.53 Mn |
| Jun 30, 2021 | 3.80 Mn |